Select your country

20.12.2018
STADA’s EUR 300,000,000 1.75% Senior Notes due 2022
STADA’s EUR 300,000,000 1.75% Senior Notes due 2022

STADA and certain of its significant subsidiaries have today granted certain in rem security to secure certain capital markets indebtedness …

Read more

20.12.2018
"I want to stay with STADA for the long term." – An interview with Peter Goldschmidt
"I want to stay with STADA for the long term." – An interview with Peter Goldschmidt

Peter Goldschmidt has been the new CEO at STADA since September. In this interview he talks about his first time at STADA and his values.

Read more

06.12.2018
STADA increases its stake in Pymepharco in Vietnam
STADA increases its stake in Pymepharco in Vietnam

STADA CEO Peter Goldschmidt: "An excellent basis for becoming a key leader in Vietnam"

Read more

28.11.2018
STADA: Completion of the compliance investigation
STADA: Completion of the compliance investigation

No pending or expected legal disputes in relation to former members of the Management Board or employees.

Read more

11.10.2018
STADA WINS GGB18 AWARD
STADA WINS GGB18 AWARD

STADA wins 2018 Global Generics & Biosimilars Award in “Company of the Year, EMEA” category.

Read more

03.09.2018
STADA CEO Peter Goldschmidt
STADA CEO Peter Goldschmidt

Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO

Read more

06.08.2018
Strategic portfolio expansion
Strategic portfolio expansion

STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG

Read more

20.07.2018
STADA Launches Anti-Cancer Drug Pemetrexed
STADA Launches Anti-Cancer Drug Pemetrexed

STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.

Read more

18.07.2018
STADA Repurchases Rights for Ladival
STADA Repurchases Rights for Ladival

STADA Arzneimittel AG and Ladival GmbH & Co KG have agreed to transfer the rights for the sunscreen Ladival back to the German pharmaceu…

Read more

12.07.2018
Xbrane and STADA enter into a co-development agreement for Xlucane
Xbrane and STADA enter into a co-development agreement for Xlucane

Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…

Read more

28.06.2018
Strategic expansion of OTC portfolio continues – STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica
08.06.2018
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022

STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.

Read more

06.06.2018
STADA: Annual General Meeting approves agenda items with a large majority
STADA: Annual General Meeting approves agenda items with a large majority

STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…

Read more

16.04.2018
Changes in the management team of STADA
Changes in the management team of STADA

STADA is systematically pushing ahead with the new strategy announced in March.

Read more

23.03.2018
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

Read more

20.03.2018
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer

STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…

Read more

08.03.2018
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

Read more

08.03.2018
More focused and aggressive
More focused and aggressive

At the press conference on March 8, 2018 STADA CEO Dr. Claudio Albrecht presented his vision for STADA and the company’s new strategy. In th…

Read more

08.03.2018
STADA records positive business development in 2017
STADA records positive business development in 2017

STADA records positive business development in 2017

Read more

08.03.2018
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…

Read more

02.03.2018
STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim
STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim

STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim

Read more

02.02.2018
STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH
STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…

Read more

01.02.2018
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…

Read more